LMO2

Across TCGA pan-cancer cohorts, LMO2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LMO2 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LMO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMO2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

UCEC and LSCC are the cancer types where LMO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.429	1.000	.036	8	view →
LSCC	DFS	Tertile	II,III,IV	0.888	0.252	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LMO2–UCEC (DFS)

Open the UCEC breakdown →